JNK

JNK-IN-8 (JNK Inhibitor XVI) is an irreversible JNK1/2/4 inhibitor (IC50: 4.7/18.7/1 nM) with over 10-fold selectivity compared to MNK2 and Fms, and no inhibition of Met, c-Kit, or PDGFRβ in the A375 cell line.

TCS JNK 5a (SC202671) is an effective, specific inhibitor of JNK3(pIC50= 6.7), JNK2(pIC50=6.5).

JNK-IN-7 (JNK inhibitor) is a selective JNK1/2/3 inhibitor (IC50: 1.54/1.99/0.75 nM). It can also inhibit phosphorylation of c-Jun, which is a substrate of JNK kinase.

JNK-IN-11 (compound 1) is a potent inhibitor of JNK, with IC50 values of 2.2 μM, 21.4 μM, and 1.8 μM for JNK1, JNK2, and JNK3, respectively, showing potential for Alzheimer's and Parkinson's disease research.

JNK Inhibitor VIII (TCS JNK 6o) is an ATP-competitive, selective inhibitor of c-Jun N-terminal kinase (JNK) with IC50 values of 45 nM for JNK-1 and 160 nM for JNK-2.

SP600125 (JNK Inhibitor II) is a JNK inhibitor that inhibits JNK1, JNK2, and JNK3 (IC50=40/40/90 nM) with oral potency, reversibility, and ATP-competitive properties. SP600125 inhibits autophagy and induces apoptosis.

(E)-Ferulic acid methyl ester (Methyl (E)-ferulate) is a potential inhibitor of the mitogen-activated phosphor kinase pathway and an anti-inflammatory agent first isolated from the medicinal plant S. tuberosa. Additionally, it shows promising anthelmintic activity against Haemonchus contortus.

(-)-Bornyl acetate (L-(-)-Bornyl acetate) is a less active enantiomer of (+)-Bornyl acetate. Isolated from hyssop oil, it possesses antifungal, highly active whitening, and antioxidant properties, and it has potential applications in cosmeceutical materials. It downregulates proinflammatory cytokines in vitro and in vivo, reduces the number of total cells, neutrophils, and macrophages in BALF, attenuates histologic lung alterations, decreases the wet-to-dry weight ratio in BALF, and inhibits the activation of NF-kappa-B inhibitor alpha, extracellular regulated protein kinases, c-JunN-terminal kinase, and p38 mitogen-activated protein kinase.

JNK-1-IN-3 (Compound 9e) acts as a JNK1 inhibitor, both reducing JNK1 gene expression and lowering the protein levels of its phosphorylated form. It concurrently diminishes the expression of downstream targets c-Jun and c-Fos in tumors, while also restoring p53 activity. Exhibiting broad-spectrum antiproliferative effects, JNK-1-IN-3 is particularly effective against renal and breast cancer cell lines, showing significant anticancer activity both in vivo and in vitro.

JNK-1-IN-4 (Compound E1) is an inhibitor of JNK, targeting JNK-1, JNK-2, and JNK-3 with IC50 values of 2.7, 19.0, and 9.0 nM, respectively. This compound inhibits the phosphorylation of c-Jun and reduces the expression of TGF-β1-induced EMT markers (such as fibronectin and α-SMA). JNK-1-IN-4 exhibits favorable pharmacokinetic properties with a bioavailability of 69%. Additionally, it demonstrates antifibrotic effects in a Bleomycin-induced mouse model of idiopathic pulmonary fibrosis.

JNK-IN-21 (Compound 62) is an inhibitor of JNK-1.

JNK-IN-22 (Compound 58) is a JNK-1 inhibitor.

JNK-1-IN-5 (Compound 14) is a potent JNK1 inhibitor with sub-nanomolar efficacy. It effectively inhibits TGF-β-induced epithelial-mesenchymal transition and shows promise for research targeting JNK1 as an anti-pulmonary fibrosis agent.

DB07268 is a potent and selective JNK1 inhibitor. It exhibits a strong affinity for the JNK1 enzyme, effectively inhibiting its activity and providing potential therapeutic benefits in conditions where JNK1 is implicated. This compound has demonstrated selective binding to JNK1 over other kinases, underscoring its specificity and promising application in targeted therapies.

15(S)-HpETE is a product of arachidonic acid formed in the 15-lipoxygenase pathway and inhibits angiogenesis. 15(S)-HpETE can upregulate the expression of CD31, E-selectin, and gene selectin in cells.

IQ-1S free acid (IQ-1S) is an effective and specific c-Jun N-Terminal Kinase Inhibitor. IQ-1S inhibits murine delayed-type hypersensitivity. IQ-1S can reduce inflammation and cartilage loss associated with CIA and can serve as a small-molecule modulator for mechanistic studies of JNK function in rheumatoid arthritis. IQ-1S is highly specific for JNK and that its neutral form is the most abundant species at physiologic pH.

Loureirin B can downregulate the expression of fibrosis-related molecules by regulating MMPs and TIMPs levels, inhibit scar fibroblast proliferation and suppress TGF-β1-induced fibrosis, during which TGF-β1/Smad2/3 pathway is likely involved.

Apelin-12 acetate possesses a high affinity to orphan receptor APJ receptor. Apelin-12 acetate inhibits the JNK and p38 MAPK signaling pathway of the apoptosis-related MAPKs family, thus offering protection to neurons.

Vincristine binds to tubulin and inhibits the formation of microtubules, thereby inhibiting mitosis of the cancer cell. Vincristine can be used as a microtubule-destabilizing agent for research on the treatment of hematologic cancers, such as leukemia and

Phytolaccaceae has anti-tumor activity, the mechanism may be related to the capacity of Esculentoside H for TNF release.

Astragaloside, one of the main active ingredients in Astragalus membranaceus.

Tomatidine hydrochloride (Tomatidine HCl) is a steriodal alkaloid structurally similar to Cyclopamine but does not inhibit hedgehog pathway. May be used as a negative control for Cyclopamine and KAAD-Cyclopamine. Tomatidine protects against muscle atrophy and boosting muscle growth.

1. beta-Asarone (Cis-Isoelemicin) may be a potential preventive drug for Alzheimer's disease. 2. Beta-Asarone prevents autophagy and synaptic loss by reducing ROCK expression in SAMP8 mice. 3. The co-administration of beta-Asarone(Cis-Isoasarone) and l-dopa may contribute to the treatment of 6-OHDA-induced damage in rats by inhibiting autophagy activity. 4. Beta-Asarone exhibits anti-inflammatory effects by suppressing the production of pro-inflammatory mediators through NF-κB signaling and the JNK pathways in activated microglial cells and might be developed as a promising candidate to treat various neuroinflammatory diseases.

CC-401 Hydrochloride (CC401 HCl) is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor (Ki of 25 to 50 nM.)with potential antineoplastic activity.